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I. INTRODUCTION
The patenting of medical and surgical procedures has become a
common practice with numerous patent applications filed on a
weekly basis.' This trend has led to current legislation before the
* Copyright 0 1996 Linda Rabin Judge.
t B.S. Chemistry & Biology, Sonoma State University; M.S. Environmental Chemis-
try, University of California at Berkeley; J.D. Santa Clara University School of Law (expected)
1997.
1. The Patent and Trademark Office issues approximately fifteen medical procedure
patents each week. See Patents Seem Fatal for Medical Ethics, Wis. ST. J., Aug. 28, 1995, at
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House and Senate aimed at minimizing or eliminating the practice.2
Some medical organizations have deemed the practice of patenting
medical and surgical procedures unethical. 3 In 1994, the American
Medical Association House of Delegates passed a resolution con-
demning the practice.4 In sharp contrast, the patenting of medical
procedures was declared essential to the future of scientific innova-
tion by members of the biotechnology industry.5
The controversy has been highlighted by a recent lawsuit filed
by Dr. Samuel Pallin. In the lawsuit, Dr. Pallin alleged that another
physician infringed his patent6 on a surgical procedure used to per-
form cataract surgery without sutures.7 Dr. Pallin attempted to
charge those who used his patented procedure8 (which was widely
used9) royalties. The outcome of the Pallin lawsuit will influence the
future allowance and enforcement of medical method patents. If such
patents are allowed, patients and insurance companies will face sig-
nificant increases in health care costs. 10
This comment reviews the current legislation and issues sur-
rounding the role of the legislature in setting forth a solution to the
dilemma regarding patenting of medical procedures. The potential
7A; see also Wendy W. Yang, Patent Policy and Medical Patents: Case for Statutory Exclu-
sion from Patentability, 1 B.U. J. SCL & TECH. L. 5 (1995).
2. Do Patents Belong in Traditional Medicine?; Congress Considering Bills that
Eliminate Protection, LEGAL INTELLIGENCER, Nov. 2, 1995, at 9 [hereinafter Do Patents Be-
long]; see also Medical Procedures Innovation and Affordability Act, H.L 1127, 104th Cong.
(1995) (introduced by surgeon Representative Greg Ganske (R-Iowa) and Ron Wyden (D-
Ore)); see also Medical Procedures Innovation and Affordability Act, S. 1334, 104th Cong.
(1995) (introduced by physician Senator Bill Frist (R-Tenn)).
3. Such medical organizations include the American Society of Cataract and Refractive
Surgery, the American Academy of Ophthalmology, the American Urological Association and
the American Association of Medical Colleges. See, e. g., Agency Opposes Bills to Create Pat-
ent Exception for Medical Procedures, BNA HEALTH CARE DAiLY, Oct. 20, 1995 [hereinafter
Agency Opposes Bills].
4. Susan Hershberg Adelman, An Earful About Why Lawyers Support Process Patents,
38 A. MED. NEWS 34, 35 (1995); see also Medical Procedures Innovation and Affordability
Act: Hearings on HR. 1127 Before the Subcommittee on Courts and Intellectual Property
Committee of the House Judiciary Committee, 104th Cong. (Oct. 19, 1995) [hereinafter Hear-
ings] (testimony of Carlos J. Moorhead, Chairman, House Judiciary Courts and Intellectual
Property Pending Legislation).
5. Agency Opposes Bills, supra note 3.
6. U.S. Patent No. 5,080,111.
7. Pallin v. Singer, No. 93-202, 1995 U.S. Dist. LEXIS 20824 (D. Vt. May 1, 1995).
8. Ron Stodghill II, First, Do No Harm. Then, Get a Patent, BUS. WK., July 24, 1995,
at 86.
9. Hearings, supra note 4 (testimony of Charles Kelman, M.D., President American
Society of Cataract and Refractive Surgery stating that at least 200 surgeons use Dr. Pallin's
technique or variations thereof).
10. Stodghill, supra note 8.
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positive and negative impacts of a ban on medical and surgical pro-
cedure patents and the effect such a restriction could have on the
medical community are discussed. The issue is analyzed from the
perspective of representatives of the medical community, the Patent
and Trademark Office (PTO), and the pharmaceutical and biotech-
nology industries.
The ethical and economic issues surrounding patenting of medi-
cal procedures should not be controlled by legislative action. In the
discussion that follows, the channels which already exist to allow
patents on medical procedures, where appropriate, will be reviewed.
In addition, a proposal for addressing the controversy regarding pat-
enting of medical procedures through the PTO, the courts," and by
way of industry policy will be presented.
IH. PATENT LAW'S IMPACT ON TECHNOLOGICAL INNOVATION
Traditional patent law has provided protection for inventions in
applied technology, but not basic scientific research. 12 Section 101 of
Title 35 of the United States Code (U.S.C.) provides in part that
"whoever invents or discovers any new and useful process, or any
new and useful improvement thereof, may obtain a patent therefor,
subject to the conditions and requirements of this title."13 The focus
on applied technology is derived in part from the language of the
Constitution, which authorizes Congress "[t]o promote the Progress
of Science and useful Arts, by securing for limited Times to Authors
and Inventors the exclusive Right to their respective Writings and
Discoveries."14
There are essentially three levels of patent law: the Constitu-
tional grant of authority for Congress to create the patent laws, 5 the
Congressional legislation, 6 and the interpretive case law.17 The
11. In 1982, Congress created the United States Court of Appeals for the Federal Circuit
(CAFC) which serves as the only Federal Appellate court for patent cases. The CAFC has
standardized many areas of patent law. See Federal Courts Improvement Act of 1982, Pub. L.
No. 97-164, 96 Stat. 25.
12. Robert P. Merges, Commercial Success and Patent Standards, Economic Perspec-
tives on Innovation, 76 CAL. L. REV. 803, 810 (1988).
13. 35 U.S.C. § 101 (1988) (in 1952 the word "art" was replaced by "process" in the re-
vised statute thereby clarifying that processes are patentable subject matter).
14. U.S. CoNST. art. I, § 8, cl. 8.
15. Id
16. Once approved a statute regulating medical procedure patents will be codified under
Title 35 of the U.S. Code.
17. See 1 DoNALD S. CHISUM, PATENTS: A TREATISE ONTHELAWOFPATENTABIL1TY,
VALIDITY AND INFRINGEMENT, § 1.03 [3], at 1-70 (1996).
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Court has stated that the promotion of science and the arts is the ob-
ject of patent protection and the reward given to inventors is secon-
dary and merely a means to that end.18
The Constitution does not elaborate on what is meant by inven-
tors or discoveries. 9 The term inventorship has no precise definition,
and no clarification on this subject has been provided by the Supreme
Court or the patent statutes.20 An invention is the practical manifes-
tation of an inventor's ideas21 and is more than a concept. Under
common law, inventorship refers to the process of conception and re-
duction to practice of a patentable invention.Y An invention should
be distinguished from an innovation which is the functional or de-
bugged version of an invention and which does not rise to a level de-
serving patent protection.23
Patent law expressly requires an inventor to disclose both the
invention and the best known mode of practicing it, in order to
"enable any person skilled in the art to make and use" the claimed
discoveries. 24 Patent law also requires inventors to demonstrate the
utility of their inventions and excludes protection for scientific prin-
ciples or ideas.25 The grant of a patent is a powerful tool which gives
the owner the right to exclude others from making, using, or selling
an invention in the United States for a period of 20 years beginning
when the patent application is filed. At the end of the 20 year period,
the invention becomes available to the public.26 A patent grant is ini-
tiated when the inventor files a patent application. In the application
the invention must be described with sufficient detail such that one
skilled in the applicable art could practice the invention.27 The in-
18. United States v. Masonite Corp., 316 U.S. 265,278 (1942).
19. U.S. CoNST. art. I, § 8, cl. 8.
20. Hearings, supra note 4 (testimony of Charles Kelman, M.D., President American
Society of Cataract and Refractive Surgery).
21. Merges, supra note 12, at 807, 808.
22. Burroughs Wellcome Co. v. Barr Labs. Inc., 40 F.3d 1223, 1227-28 (Fed. Cir. 1994).
23. Merges, supra note 12, at 807.
24. 35 U.S.C. § 112 (1988).
25. J. H. Reichrnan, Computer Programs As Applied Scientific Know-How: Implications
of Copyright Protection for Commercialized University Research, 42 VAND. L. RPv. 639, 649
(1989).
26. 35 U.S.C.A § 154 (West Supp. 1996):
Such grant shall be for a term beginning on the date on which the patent issues
and ending 20 years from the date on which the application for the patent was
filed in the United States or, if the application contains a specific reference to an
earlier filed application or applications under section 120, 121, or 365(c) of this
title, from the date on which the earliest such application was filed.
27. 35 U.S.C. § 112 (1988).
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vention claimed must meet the statutory requirements of novelty,
utility, and nonobviousness. 28 To be novel, an invention must be dis-
tinguished from the existing technology in the relevant field. Utility
requires that the invention be useful and the nonobviouness require-
ment is met by demonstrating that the invention would not have been
easily conceived by one with an ordinary level of skill in the field to
which it pertains.29
Within a given patent application, the claim describes the scope
of the invention and is evaluated by the PTO which determines pat-
entability and delineates the property rights encompassed by the pat-
ent.3 0 The PTO examines the patent application and has the authority
to grant or deny a patent. Once issued, a patent is presumed valid
and subsequent challenges to validity generally occur in the context
of an infringement action in the Federal Court System where the al-
leged infringer asserts a defense of patent invalidity.3 1 During the ex
parte process of evaluating the merits of a patent application, the pat-
entee has a duty of complete candor relative to communications with
the PTO, and failure to satisfy this requirement can result in a loss of
rights to the patent.32 The disclosure requirements parallel scientific
norms by demanding that patent applicants, like publishing scientists,
describe their inventions to the public and supply appropriate and
sufficient information and materials to show that they have in fact
achieved what they claim.33
Published patents may be used as a source of technical informa-
tion. The purpose underlying the patent statutes is to promote inno-
vation by offering a right of exclusion for a limited period as an in-
centive to inventors to risk the costs of time and materials which may
28. 35 U.S.C. §§ 101-103 (1988).
29. A patent may not be obtained on a novel advancement in technology unless the sub-
ject matter sought to be patented and the prior art can be compared and the subject matter of
the patent as a whole would not have been obvious to one with ordinary skill in the art to
which the subject matter pertains. The modem interpretation of nonobviousness is based on a
three part test supplied by the court in Graham v. John Deere Co., 383 U.S. 1, 17 (1966). In a
nonobviousness determination, the judge is required to determine the state of the prior art be-
fore the current invention, evaluate what constitutes ordinary level of skill in the inventor's
field and determine if the difference between the current invention and the prior art should
have been obvious. This test along with secondary factors such as unfulfilled need, failure of
others in the past and commercial success contribute to the nonobviousness determination; see
35 U.S.C. §§ 101-103 (1988).
30. 35 U.S.C. § 112(1988).
31. 35 U.S.C. § 282 (1988).
32. 35 U.S.C. § 115 (1988).
33. Rebecca S. Eisenberg, Proprietary Rights and the Norms of Science in Biotechnol-
ogy Research, 97 YALE L. J. 177, 207 (1987).
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be required to create a patentable invention. However, patent law
may operate to delay the dissemination of knowledge to other re-
searchers and practitioners. Because of this delay, the patent system
threatens the interests of the scientific and medical communities in
the free use and extension of new discoveries.34
It is generally accepted that the patent system was designed to
serve the public interest by creating incentives for scientific innova-
tion.31 Such incentives are especially important in research intensive
fields like the pharmaceutical industry, where inventions do not occur
without significant investment of time and resources. 36 The conven-
tional reward structure in science and medicine motivates inventors
to make contributions to the scientific and medical communities in
order to gain recognition for the progress they have made.3 7 Once an
inventor has filed a patent application, sharing research results or
technical innovations does not interfere with patent protection for
those inventions already claimed.38 However, dissemination of sci-
entific results or techniques allows general access to the information
which is described and may help competitors make future discover-
ies. Therefore, patent applicants who are uncertain as to the patent-
ability of their inventions may choose to defer discussion of their re-
sults until a patent is actually issued because dissemination of such
information forfeits secrecy protection without any assurance of ob-
taining patent rights.39 Once a patent has been secured by the inven-
tor, those who make, use, or sell the patented invention must first
obtain a license or they may be held liable for patent infringement.40
As discussed above, the U. S. patent system has several levels of
controls on issuance and testing of the patentability of an invention.
The process of patent approval is exparte and nonadversarial. In ad-
dition, patent applications are kept secret until the respective patent
issues. In the course of this process, there is minimal opportunity for
a challenge to patentability except those challenges raised by the
PTO. Therefore, it is important that patent law provides two signifi-
cant checks on the issuance of each patent. First, inventors are re-
34. Id. at 177.
35. Evan Ackiron, Patents Criticalfor Pharmaceuticals, the AZT Case, 17 AM. J. L. &
MED. 145, 149 (1991).
36. Id.
37. Eisenberg, supra note 33, at 183, n24.
38. Patent applications are kept secret until a patent issues. 35 U.S.C.A. § 122 (West
Supp. 1995).
39. Eisenberg, supra note 33, at 216-17.
40. 35 U.S.C. § 271 (1988).
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quired to be absolutely candid when dealing with the PTO which ob-
ligates disclosure of any material information.41 Second, although
third parties may not intervene in the process of patent approval, they
may test the validity of a patent in the context of an infringement ac-
tion in the federal court system.42 These controls go a long way to-
ward providing adequate insurance that patents will not be issued and
enforced for medical procedures when it is not appropriate to do so.
m11. HISTORICAL TREATMENT OF MEDICAL PROCEDURE PATENTS
Historically, the medical profession and the courts have been
hostile to medical process patents.43 There has been a general notion
that medical and surgical procedures are not patentable as proc-
esses.44 Internal PTO decisions have recently reversed a trend which
existed since an 1883 decision45 where the Commissioner of Patents
stated that "the methods or modes of treatment of physicians of cer-
tain diseases are not patentable." 46 In a 1952 decision,47 the Patent
Office Board of Appeals reversed the long existing trend of not al-
lowing medical procedure patents. They focused on the utility of a
new method for injecting a medication with a pressure jet in their al-
lowance of the patent claim. This ruling opened the door for medical
procedure patents.48 Process patents have traditionally been used to
secure proprietary rights in the health care field; patent protection of
medical and diagnostic procedures have been far less common.49 In
41. A breach of this duty may result in the patent being declared invalid or denial of re-
lief against an alleged infringer. Duty to Disclose Information Material to Patentability, 37
C.F.R § 1.56 (1996).
42. Blonder-Tongue Labs., Inc. v. University of Ill. Found., 402 U.S. 313, 350 (1971) (if
an accused infringer overcomes the presumption of validity, there is no liability for making,
using or selling the invention and furthermore, once a patent has been invalidated in one pro-
ceeding, the patentee cannot bring subsequent infringement actions).
43. Yang, supra note 1, at 5, n12.
44. CHIsUM, supra note 17, § 1.03[3], at 1-70.
45. Yang, supra note 1, at 5, n18.
46. See CHIsUM, supra note 17, § 1.03[3], at 1-70.
47. See Becton-Dickinson & Co. v. Robert P. Scherer, 106 F. Supp. 665 (E.D. Mich.
1952) (this case stands for the proposition that processes are patentable even if they consist of
"medical or surgical methods" which involve treatment of the human body).
48. Following submission of a patent application, the PTO evaluates patentability in an
ex parte procedure where a patent examiner who represents the PTO interacts with the pat-
entee. If the patent application is denied, the patentee may appeal to the Patent Office Board
of Appeals which has the authority to reverse decisions of thd patent examiners. See Hearings,
supra note 4 (testimony of William D. Noonan, M.D., physician and patent attorney, Klarquist,
Sparkman, Campbell, Leigh & Whinston).
49. Bill Would Limit Issuance of Patents on Medical Procedures, BNA PAT.,
TRADEMARK & COPYRiGHT L. DAILY, Mar. 15, 1995, available in LEXIS, BNA Library,
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addition, patents on medical and diagnostic procedures have rarely
been enforced.5 0 Patents obtained by researchers and physicians on
medical procedures have been used mainly to claim credit for inven-
tions without the expectation of financial reward.5
The historical lack of inclination to secure or enforce patents in
the medical field and the rarity of litigation is partially based on the
premise that it is contrary to the professional ethics of doctors and
surgeons to claim exclusive rights to their discoveries or innova-
tions.5 2 Also, while the infringement of patented devices or drugs can
be easily detected by the presence of the infringing product, the en-
forcement of patents for medical procedures is much more difficult.53
In the past, it has been necessary to locate and sue each infringer
individually.5 4 In the future, with the advent of large health care or-
ganizations with computerized databases of patient information, en-
forcement of such procedure patents will be easier.55 As market pres-
sures and the increasing dominance of large Health Maintenance
Organizations reduce income for physicians, patent holders are more
likely to consider the potential for profit from their discoveries.5 6
Examples of recent patent applications filed on medical and sur-
gical techniques include a method for immobilizing a patient's arms
overhead in a prone position during a medical procedure,5 7 a method
for performing a percutaneous medical procedure without a trocar,58
and a method and apparatus for delivering a stable gas mixture to a
patient.59 The scope of such procedure patents is further illustrated
by a patent issued for a procedure and balloon catheter system for
enlarging the cross-sectional area of a fluid flow passageway60 and a
procedure and device wherein a fiber optic bundle is used to remotely
BNAPTD File [hereinafter Bill WouldLimitlssuance].
50. Reid G. Adler & Kate H. Murashige, Biomedical Product Patent Protection Essen-
tial to High-Tech Economy, LEGAL BACKGROUNDER, Feb. 2, 1996, available in LEXIS, News
Library, WLF File.
51. Id.
52. William D. Noonan, Patenting Medical Technology, 11 J. LEGAL MED. 263, 263-65
(1990).
53. Id
54. Id.
55. Id.
56. Brian McCormick, Just Reward or Just Plain Wrong? Specter of Royalties from
Method Patent Stirs Debate, 33 AM. MED. NEWS 3 (1994) [hereinafter Just Reward].
57. U.S. Pat. No. 5,410,769.
58. U.S. Pat. No. 5,383,886.
59. U.S. Pat. No. 5,335,653.
60. U.S. Pat. No. 5,180,367.
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view the operative end of a catheter.61 The subject matter of medical
and surgical procedure patents covers a broad range of topics in-
cluding using ultrasound to determine the sex of a fetus, treating im-
potence, combining drugs and vitamins to treat cancer, treating pain,
suturing internal organs, grafting skin, as well as diagnosing and
treating heart problems. 62
As summarized above, it is clear that inventions based on medi-
cal or surgical procedures can meet the basic criteria of patentability
and the PTO is now routinely issuing patents on such inventions.
What is not yet clear is how strenuously the patents will be enforced
and whether the courts will uphold the presumption of validity
awarded by the PTO. Procedures require varying amounts of invest-
ment in terms of time and resources to be developed. The tests ap-
plied by the PTO only indirectly consider this fact in awarding a pat-
ent.6 3 A new technique which requires little or no investment may be
patentable if it meets the statutory criteria. In contrast, a complex
new technique which required significant investment may be seen as
either not novel or obvious and its patentability may be denied by the
PTO. Legislation to amend the patent statutes may not be the an-
swer, but clearly the awareness of these issues and a standard policy
by the PTO is needed to guide the development of new medical and
surgical procedures.
IV. MEDICAL AND SURGICAL PROCEDURES PATENTS IN OTHER
COUNTRIES
Approximately eighty countries do not allow medical method
patents.64 Under the General Agreement on Tariffs and Trade
(GATT) and the North American Free Trade Agreement (NAFTA),
member countries may exclude from patentability "diagnostic; thera-
peutic and surgical methods for the treatment of humans or ani-
mals. '6 The clear trend in many foreign countries including Canada
61. U.S. Pat. No. 4,945,895.
62. Greg Borzo, Method Patent Fails; Court: Surgeon Doesn't Have to Pay Royalties,
39 AM. MED. NEWS, Apr. 15, 1996, at 1.
63.' See, e.g., Panduit Corp. v. Dennison Mfg., 810 F.2d 1561, 1564 (Fed. Cir. 1987)
(where in an infringement action by a manufacturer of plastic cable ties, the CAFC held a
finding of nonobviousness was supported by the patentee's investment of seven years and mil-
lions of dollars in order to develop a successful product).
64. Reginald W. Rhein, Jr., BIO, AMA Clash over Bill to Shield Health Pros from Suits
Over Procedures, BIO=EmNOLOGY NEWSWATCH, Nov. 20, 1995 (quoting H. Dunbar Hoskins,
Jr., executive vice president of the American Academy of Ophthalmology).
65. Agreement on Trade-Related Aspects of Intellectual Property Rights, Apr. 15, 1994,
Marrakesh Agreement Establishing the World Trade Organization [hereinafter WTO Agree-
1997]
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and Great Britain is to ban patenting of medical processes,66 and the
European Community is moving towards an absolute prohibition of
medical process patents.6 7
V. CURRENT LEGISLATION REGARDING MEDICAL PROCEDURE
PATENTS
A July 24, 1996 spending bill68 approved by the House included
an amendment which would prohibit the PTO from using any funds
to issue patents on medical procedures.6 9 The amendment was simi-
lar to the House version of the Medical Procedures Innovation and
Affordability Act (H.R. 1127)70 which was recently debated. How-
ever, the amendment included exemptions for processes that are part
of a patentable product and new indications for nonpatentable drugs
and biologic products such as gene therapy whose effect was not pre-
viously known or obvious. Representatives of the biotechnology and
pharmaceutical industries were extremely concerned that the inter-
pretive uncertainty of the amendment could deter vital medical re-
search. 71 The amendment was part of an appropriations bill, and
therefore, it is valid for only one year.72 On September 30, 1996,
President Clinton signed into law an appropriations bill which in-
cluded a provision changing the law relative to medical procedure
ment], Annex 1C, Legal Instruments - RESULTS OF THE URAGUAY ROUND vol. 31; 33 I.L.M.
81, 83-111 (1994) [hereinafter TRIPS Agreement]; see also Canada- Mexico - United States:
North American Free Trade Agreement, done at Washington on Dec. 8 and 17, 1992, at Ot-
tawa on Dec. 11 and 17, 1992, and at Mexico City on Dec. 14 and 17, 1992, art. 1709, § 3(a),
32 I.L.M., 605, 673.
66. See United Kingdom Patents Act, 1977, Part I, § l(1)(c) (Eng.) and Canada Patent
Act, R.S.C. ch. P-4, § 2 (1985) (Can.).
67. The European Patent Convention expressly excludes from patentability "methods for
treatment of the human or animal body by surgery or therapy and diagnostic methods practiced
on the human or animal body." European Patent Convention, Oct. 5, 1973, art. 52(4), 1
B.D.I.E.L. 986, as amended by Decision of the Administrative Council of the European Patent
Organization Dec. 21, 1978.
68. House Adopts Rep. Ganske's Amendment on Funds for Medical Procedure Patents,
BNA PAT., TRADEMARK & COPYRIGHT L. DALY, July 26, 1996 (the bill (H.R. 3814) was a
spending bill for departments of Commerce, Justice and State and was approved 246-149 by
the House).
69. Charles Craig, Biotech Backers Fear Medical Patent Ban will Hurt Industry,
BIOWORLD TODAY, July 26, 1996.
70. See infra Part V.
71. Craig, supra note 69.
72. House Adopts Rep. Ganske's Amendment on Funds for Medical Procedure Patents,
supra note 68 (a representative of the PTO's Office of Legislative and International Affairs
stated that the amendment would not amend the Patent Act so inventors can continue to file
applications on medical processes, however, the PTO is not clear on what to do with them at
this point).
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patents. The bill reflects a compromise between industry representa-
fives and the various groups which support a ban on medical proce-
dure patents.73 The medical procedures revision creates a new sub-
section [c] to 35 U.S.C. § 287 whereby a patent owner is unable to
collect damages from a "medical practitioner" who performs a
"medical activity."74
The original Senate and House bills -S. 1334, H.R. 1127-
were aimed at eliminating patent protection for medical procedures,
and are believed by some members of the medical and legal commu-
nities to be contrary to the patent system's purpose which is to induce
those with medical training to research and develop products. 75 Bill
opponents included the American Bar Association (ABA), members
of the biotechnology and pharmaceutical industries, the PTO,7 6 the
Pharmaceutical Research and Manufacturers of America (PhRMA),77
and numerous patent attorneys.78
Others believe legislation is necessary to preserve the free ex-
change of information that is at the foundation of current medical
practice 79 and support some type of legislation to either ban or control
issuance of medical and surgical procedure patents. Those who sup-
port legislation to ban medical and surgical procedure patents include
the American Society of Cataract and Refractive Surgery, the Ameri-
can Academy of Ophthalmology, the American Urological Associa-
tion, the Association of American Medical Colleges, and the Ameri-
can Medical Association (AMA).80
73. See General Provisions of the Defense Appropriations Conference Report, 1996,
H.R. 3610, Title VI, § 616.
74. In the revised version of 35 U.S.C § 287(2)(A), a "medical activity" is defined as
"the performance of a medical or surgical procedure on a body," but excludes (i) the use of a
patented machine, manufacture, or composition of matter in violation of such patent, or (ii) the
practice of a patented use of a composition of matter in violation of such patent, or (iii) the
practice of a process in violation of a biotechnology patent. However, 35 U.S.C § 287(2)(F)(
limits this by stating that remedies would still be available where the claim of a patented use of
a composition of matter contributes to the novelty. See also BNA PAT., TRADEMARK &
COPYRIGHT L. DAILY, Oct. 7, 1996 (stating that a conference summary explains that such uses
include novel uses of drugs, novel uses of chemical or biological reagents for diagnostic pur-
poses, novel methods of combining drug therapies and novel methods of providing genetic or
other biological therapies to a patient such as gene therapy).
75. Agency Opposes Bills, supra note 3.
76. Do Patents Belong in Traditional Medicine?; Congress Considering Bills that
Eliminate Protection, LEGAL INTELLIGENCER, Nov. 2, 1995; see also infra Part DC.
77, Craig, supra note 69.
78. Adler and Murashige, supra note 50.
79. Hearings, supra note 4 (testimony of Charles Kelman, M.D., President American
Society of Cataract and Refractive Surgery).
80. Do Patents Belong, supra note 2.
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The House version of the Medical Procedures Innovation and
Affordability Act (II.R. 1127) would have banned the PTO from
granting patent protection for any "invention or discovery of a tech-
nique, method or process for performing a medical or surgical proce-
dure, administering a surgical or medical therapy, or making a medi-
cal diagnosis."8  The bill contained an exception for when such
techniques are performed as a necessary component of a patentable
medical device or machine wherein the patent claims the technique,
method, or process.82
The Senate version of the Medical Procedures Innovation and
Affordability Act (S. 1334) would have created an exemption from
liability for patients, physicians, other licensed health care practitio-
ners, and any health care entity with which such personnel are affili-
ated.83 The exclusion would have covered use of, or inducement to
use, "patent[ed] technique[s], method[s] or process[es] for perform-
ing surgical or medical procedure[s], administering a surgical or
medical therapy, or making a medical diagnosis." 4 It would not have
impacted those who make or sell pharmaceuticals or medical devices
which are regulated by the Food and Drag Administration. 85 The op-
erations of the PTO would not have been impacted by S. 1334 be-
cause it applied to enforcement of patents rather than issuance.
Heated testimony was presented at hearings before the Sub-
committee on Courts and Intellectual Property of the House Judiciary
Committee, where opponents of H.R. 1127 testified that the bill
would interfere with the essence of protection needed for continued
sponsorship of research and development. 6 G. Lee Skillington, PTO
Counsel for Legislative and International Affairs, represented the
view of his organization, stating that H.R. 1127 was not the proper
way to address the concerns of its proponents and proposed that the
PTO conduct hearings to create an administrative solution to the
problem. 87
Dr. Greg Ganske, sponsor of H.R. 1127, spoke in support of
81. Medical Procedures Innovation and Affordability Act, H.R. 1127, 104th Cong.
(1995).
82. Id.
83. Id.
84. Id.
85. Agency Opposes Bills, supra note 3.
86. Hearings, supra note 4 (testimony of Dr. Frank Baldino, Jr., President and CEO of
Cephalon Inc.).
87. Hearings, supra note 4 (testimony of G. Lee Skillington, Counsel with the Office of
Legislative and International Affairs of the Patent and Trademark Office).
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legislation to eliminate medical procedure patents, and expounded
upon the medical tradition of sharing information and techniques for
the public benefit."8 His testimony emphasized that there is no need
to allow patents on medical and surgical procedures. The absence of
high costs for developing or testing such methods and the lack of
manufacturing and regulatory costs are in contrast to the huge costs
which justify patents for other types of inventions such as new medi-
cal devices and drugs.8 9 Ganske added that physicians may be reluc-
tant to share medical information for fear of allegations of patent in-
fringement or inducement of infringement. This reluctance is a
major concern of proponents of the legislation9° because they believe
the trend towards extensive patenting of medical procedures will re-
sult in reduced availability of new treatments for patients.91 These
fears are well founded if patent holders, such as Dr. Pallin, prevail in
their infringement suits.92
Speaking in favor of H.R. 1127, Charles Kelman, M.D., Presi-
dent of the American Society of Cataract and Refractive Surgery,
testified that "the intentional withholding of new skills and tech-
niques for personal gain is unhealthy for patients, inhibits medical
progress, and is inconsistent with the Hippocratic Oath."93 Dr. Kel-
man further stated that new medical procedures are the result of the
exchange of information between physicians regarding new tech-
niques or variations of existing ones.94 Kelman alleges that patents,
such as Pallin's for a frown-style incision used in cataract surgery to
make self-healing wounds, represent refinements of existing proce-
dures and should not meet the requirements of a patentable inven-
tion.95 It has been argued that Congress must act in this area because
courts have been deferential to Congressional policy relative to pat-
ent issues.96
Those who support a ban urge that the time needed to investi-
gate ownership of a new procedure, the fear of allegations of patent
88. Hearings, supra note 4 (testimony of Dr. Greg Ganske, surgeon and Congressman
(R-Iowa)).
89. Id.
90. Agency Opposes Bills, supra note 3.
91. Rhein, supra note 64, at 35.
92. See infra Part VI.
93. Hearings, supra note 4 (testimony of Charles Kelman, M.D., President American
Society of Cataract and Refractive Surgery).
94. Id.
95. Id.; see also supra Part II.
96. Gregory F. Burch, Ethical Considerations in the Patenting of Medical Processes, 65
TEX. L. REV. 1139, 1162(1987).
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infringement, and the tendency to file patents in order to protect
one's interests can only detract from rapid dissemination of new
ideas. In support of this position, the Director of Georgetown Uni-
versity Bioethics Center, LeRoy Walters, stated that "had the kidney
transplantation or cardiac catheterization been patented as proce-
dures, it seems likely that their diffusion into the clinical context
would have been delayed and patient costs increased.
97
Some organizations favored one version of the bill over the
other. For example, the Medical Procedure Patent Coalition 98 fa-
vored the Senate version of the bill because it allowed the PTO to
continue to issue patents on medical and surgical procedures without
limitations and thereby ensured that the availability, quality, and af-
fordability of medical and surgical procedures would not be com-
promised. Under the Senate bill, pharmaceutical companies, device
manufacturers, and biotechnology companies could continue to en-
force their rights against commercial entities that infringed or in-
duced infringement of their patents. 99 The Senate version of the bill
attempted to gain the biotechnology industry's support by allowing
enforcement of some patent claims for medical techniques. 1'0
Speaking for one of the numerous groups which did not support
either version of the bill, Donald R. Dunner, Chairman of the Intel-
lectual Property Law Section of the American Bar Association, testi-
fied that the goal of the patent system is to provide incentives for in-
novation for "any and all subject matter."'101 Dunner further testified
that it would be unfair to single out any area of subject matter and
deny rewards for creativity in that area. 02 He explained that the fact
that the U.S. patent system has been instituted with statutory guide-
lines reflects a national policy that the benefit of patenting outweighs
the costs. 03 Dunner further argued that the patent system promotes
97. Embryo Transfer Technique Patent Questioned by Rep. Gore, House Subcommittee
Should Review Generic Issue of Medical Process Patents, Ethicist Says, 27 BLUE SHEET 34, at
4-5 (1987) [hereinafter Embryo].
98. See infra note 126.
99. Hearings, supra note 4 (testimony of Charles Kelman, M.D., President American
Society of Cataract and Refractive Surgery).
100. Rhiein, supra note 64.
101. Hearings, supra note 4 (testimony of Donald R. Dunner, ABA Chairman of the In-
tellectual Property Law Section); see also Diamond v. Chakrabarty, 447 U.S. 303, 315 (1980),
(where the Supreme Court stated that "The Congress intended that statutory subject matter to
include anything under the sun that is made by man.").
102. Hearings, supra note 4 (testimony of Donald R. Dunner, ABA Chairman of the In-
tellectual Property Law Section).
103. Id.
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dissemination of information, 1°4 which contradicts the view of sup-
porters of the ban on medical and surgical procedure patents.
Proponents of a ban on medical process patents are also con-
cerned that a patent examiner's seal of approval on a medical proce-
dure patent may be misinterpreted by the general public as approval
by highly trained medical experts.105 In contrast, those in favor of
awarding medical procedure patents feel that the PTO is fully quali-
fied to critically evaluate and award patents for medical or surgical
procedures when appropriate, even in the absence of any specialized
training in the field.' °6
In addition, some lawyers and doctors argue that the trend to-
wards managed care in the health care industry will make it easier to
collect royalties derived from patent licenses.107 Also, physician re-
sistance to patenting may decrease or physicians may have no choice
given the trend towards administration of health care by large corpo-
rations who will dictate policies to protect their interests.
The Senate bill was more reasonable than the House version,
because it exempted physicians, patients, and other licensed health
care professionals and entities from liability for infringement from
using patented medical processes. However, interpretive difficulty
could raise issues as to who would qualify as a "patient, physician, or
other licensed healthcare practitioner, or any health care entity with
which a physician or licensed health care practitioner is profession-
ally affiliated."'0 Arguably, it is not fair to allow a patent to be en-
forced for some applications and not others. The Biotechnology In-
dustry Organization (BIO) still opposes the legislation because of the
potential impact on acquisition or enforcement of patents for bio-
technology inventions, which may be limited based on interpretation
of the language of the statute once enacted. 109
If medical and surgical procedure patents become common be-
cause a legislative ban is not implemented and patentees are success-
104. Id. See also infra Part VIII.
105. ASCRS Files Complaints Over Deceptive Advertisements by Samuel Pallin, MD Re-
garding Invention of Surgery, PR NEWSWI E, May 24, 1996, available in LEXIS-NEXIS,
NEWS Library, PRNEWS File.
106. Hearings, supra note 4 (testimony of Donald R. Dunner, ABA Chairman of the In-
tellectual Property Law Section).
107. McCormick, supra note 56 (quoting James Longacre, counsel for Dr. Pallin).
108. Medical Procedures Innovation and Affordability Act, S. 1334, 104th Cong. (1995).
109. Id. (citing Chuck Ludlam, BIO's vice-president for government relations); see also
Michelle L. Robinson, House Passes Biotechnology Patent Process Bill, Action of Other Bills
Pending, BIOWORLD TODAY, Oct. 19, 1995, at 6.
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ful in infringement actions, there will be an effect on incremental im-
provements in techniques as well. The incentive will be to file pat-
ents on any improvement potentially eligible for patent protection,
thereby changing the way medical practitioners interact in the regular
course of their business. Physicians who have no interest in protect-
ing their own proprietary rights will run up against the intellectual
property system when they try to gain access to other medical or sur-
gical techniques. Physicians, personally, may not fear infringement
allegations or support patenting of medical or surgical procedures.
However, as large health maintenance organizations increase their
control of medical care, they will likely be dictating policies not only
requiring physician employees to patent their own techniques, but
also to not use those of others. Under a system, where patents for
medical and surgical procedures are freely allowed and enforced,
even unjustified fears of infringement suits, will engender uncertainty
and reluctance to employ techniques possibly owned by someone
else.
If a patent owner prevails in an infringement lawsuit and col-
lects damages, it will fuel the building concern on the part of health-
care practitioners that payment of damages for patent infringement is
a real possibility which must be factored into any decision to use a
new technique. Physicians may make a preemptive decision and shy
away from techniques which they believe belong to another physician
or health care organization rather than risk the possibility of a law-
suit. In addition, if a patent owner prevails in an infringement law-
suit, large health care organizations, who employ the majority of
physicians in the United States, will also become concerned about
potential litigation and instruct their physician employees to behave
cautiously when trying new procedures. Although this would chill
the implementation of a procedure such as a new life saving tech-
nique, it would have a far greater impact on improvements to existing
procedures. A physician would almost certainly risk a patent in-
fringement suit to save the life of a patient. However, the potential
for an impact on life saving innovations does exist if a ban on medi-
cal process patents is implemented. In either case, if a legislative ban
is put in place, dissemination of new techniques and ideas will be
delayed while the ownership of rights to various methods is resolved.
VI. LAWSUITS INVOLVING MEDICAL PROCEDURE PATENTS
The issue of medical and surgical procedure patents has been
brought to the forefront by a patent infringement lawsuit involving a
widely used technique for cataract surgery which utilizes a special
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incision and no sutures. Dr. Samuel Pallin filed a lawsuit against Dr.
Jack Singer alleging that Singer not only used his patented incision
for cataract surgery," 0 but induced others to infringe the patent by
publishing medical journal articles about the'surgical technique and
instructing others in how to use the procedure."' This is believed to
be the first case in which one physician has sued another for patent
infringement involving a surgical procedure.112 Dr. Singer feels that
to avoid such lawsuits, other medical practitioners must withhold
new and useful methods rather than freely exchange them with col-
leagues and/or conduct regular patent searches and file patent appli-
cations prior to sharing ideas.113 Dr. Singer is also of the opinion that
mandatory disclosure in patent applications, even as early as six
months after the filing date;would delay the use and improvement of
new medical procedures.114 Opponents of proprietary rights to medi-
cal procedures claim that prior to issuance of a patent (which may
take several years), it is in the patentee's interest to keep the inven-
tion secret. 5 A proposed rule that patents be published 18 months
after filing1 6 will, if enacted, partially alleviate this concern because
earlier publication will be a part of the patenting process.
Dr. Pallin defended the patent in response to the complaints of
fellow ophthalmologists, who had been critical of him for claiming
ownership of the surgical procedure which he patented. Pallin claims
that he turned to the PTO because he was denied the opportunity to
publish his findings in a traditional medical journal' 1 7 However, Dr.
George Lundberg, Editor of the Journal of the American Medical As-
sociation said he could not imagine that given the thousands of peer-
reviewed journals in existence that a researcher could not find an
outlet for his work.1 8 With estimates that as many as half of all cata-
110. U.S. Pat. No. 5,080,111; see also supra Part I.
111. Pallin v. Singer, No. 93-202, 1995 U.S. Dist. LEXIS 20824 (D. Vt. May 1, 1995);
see also Hearings, supra note 4 (testimony of Dr. Jack Singer, ophthalmologist from Dart-
mouth-Hitchcock Medical Center, Randolph, Vermont).
112. Lee Bowman, Physicians Stake Claims to their Art of Healing; Courts will rule on
Patents, While Medical Societies Denounce Them as Unethical, Harpful, S.F. EXAM., July 16,
1995, at B-1.
113. Hearings, supra note 4 (testimony of Dr. Jack Singer, ophthalmologist from Dart-
mouth-Hitchcock Medical Center, Randolph, Vermont).
114. Id.
115. McCormick, supra note 56.
116. See H.R. 1733, 104th Cong. (1995).
117. Hearings, supra note 4 (testimony of Samuel Lear Pallin, M.D., Medical Director
Lear Eye Clinic, Scottsdale, Arizona).
118. McCormick, supra note 56.
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ract procedures employ Dr. Pallin's technique, potential earnings
from licensing fees could be substantial.1 9 Pallin expressed a fre-
quently argued position that based on the Constitutional basis for pat-
ent protection, 20 supporters of legislation to ban medical procedure
patents are making an artificial distinction between medical proce-
dures and devices.' 21
Pallin's view mirrors that of many who oppose any controls on
issuance or enforcement of medical or surgical procedure patents. He
claims the historical reluctance to enforce medical procedure patents
against doctors is based on practical enforcement issues, not ethical
concerns.' He also presented the argument that royalties and li-
censing fees are a powerful incentive in a capitalist system and can
only motivate doctors to develop new, innovative techniques, stating
that doctors would not refrain from using the "best" technique avail-
able because of greater costs.'2
Dr. Pallin's approach implies that the increased cost to the pa-
tient as the result of royalty payments on a patent is not a factor in the
debate over whether Congress should intervene and limit patenting of
surgical procedures. Given the current economic pressures on the
medical community and the trend towards cost containment in the
health care industry, this argument has limited merit.124
A federal district judge issued a consent order in the case invali-
dating all of Dr. Pallin's claims of ownership of the procedure for
119. McCormick, supra note 56; see also Stodghill, supra note 8 (stating that Pallin is
trying to collect royalties of $5 per operation from approximately 2000 eye surgeons who per-
form an estimated 500,000 procedures per year).
120. Kewanee Oil v. Bicron Corp., 416 U.S. 470 (1974) (explaining that patent laws
"promote the progress of science and useful arts" by offering a right to exclude others from an
invention for a limited period of time as an incentive to risk the costs of research and develop-
ment and associated investment of time needed to develop an invention).
121. Hearings, supra note 4 (testimony of Samuel Lear Pallin, M.D., Medical Director
Lear Eye Clinic, Scottsdale, Arizona).
122. Hearings, supra note 4 (testimony of Samuel Lear Pallin, M.D., Medical Director
Lear Eye Clinic, Scottsdale, Arizona, stating that recent advances in computerized record
keeping has eliminated the practical problem of tracking use of medical procedures in order to
determine royalties).
123. Hearings, supra note 4 (testimony of Samuel Lear Pallin, M.D., Medical Director
Lear Eye Clinic, Scottsdale, Arizona).
124. Of course, the argument can be made against the patenting of any invention for
which the cost increases associated with exclusivity suggest limiting the protection. However,
patent protection for diagnostic and therapeutic procedures are unique in that the consumer -
the patient -usually has the purchasing decision made for them by either their physician or
the physician's employer. This separation of purchaser and consumer makes the patient par-
ticularly vulnerable to not being treated with procedures which they would have purchased for
themselves, because of cost.
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sutureless cataract surgery. Pallin had demanded that Singer pay a
royalty ranging from $2,500-$10,000 per year.121 The case was dis-
missed with prejudice and Dr. Pallin was enjoined from enforcing
any of the claims of the patent against anyone else in the future. 126
Hearings, were recently conducted before the PTO in order to
determine if the issues regarding medical procedure patents could be
solved administratively as opposed to legislatively. 27 A representa-
tive of the Medical Procedure Patent Coalition 28 testified that the
PTO's prior art, even for published materials, is deficient, citing the
Pallin case as an example of a situation where the PTO should not
have issued the patent and would not have done so had it been aware
of the relevant prior art. Dr. Pallin did not bring the relevant prior art
to the attention of the PTO, and none of it was published, so the PTO
could not have been expected to be aware of it. In addition, the tech-
nique Pallin patented was the sum of many years of incremental im-
provement in a technique, and his contribution may have included
only one step in the procedure which required no capital investment.
The PTO is not equipped to gain access or properly evaluate the prior
art, given the specialization of current medical practice. 129
Prior art for medical and surgical procedural inventions is fre-
quently the exchange of information in operating rooms, at medical
schools, in conferences or seminars, and in publications in peer-
reviewed journals. This makes the examination of medical and sur-
gical procedure patents unusually difficult for the PTO. The issue of
prior art for medical and surgical procedural inventions arises in the
context of re-examination of patents as well. 30 At recent hearings
before the PTO, it was suggested that the PTO could expand its li-
125. Michelle L. Robinson, Lawsuit Claiming Medical Procedure Patent Ruled Invalid,
BIOWORLD TODAY, April 15, 1996.
126. The basis of the decision was the presentation of overwhelming evidence that other
physicians had used Dr. Pallin's allegedly "unique" technique prior to the date Dr. Pallin had
claimed to invent it. Id. See generally 35 U.S.C. § 102 (1988) (requiring novelty to obtain a
patent).
127. Public Hearing on Patent Protection for Therapeutic and Diagnostic Methods, U.S.
DEPT. OF COMM. PAT. AND TRADEMARK OFFICE, May 2, 1996 (visited Feb. 16, 1997)
<http:llwww.uspto.gov/web/offices/comlsollnoticesldiaghear.txt>.
128. The Coalition consists of 17 medical societies and associations led by the American
Society of Cataract and Refractive Surgery, and includes the AMA. ,
129. Public Hearing on Patent Protection for Therapeutic and Diagnostic Methods, supra
note 127.
130. Re-examination is a consideration of patent validity, where anyone may request that
new prior art in the form of patents or printed publications be considered in a re-evaluation of
patentability of an issued patent. The types of prior art relevant to medical procedure patents
will not come up in the context of a re-examination.
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braries to include more scientific journals and get access to videos
which have become the standard way of teaching medical and surgi-
cal techniques.13'
A number of other lawsuits for patent infringement involving
medical procedures are imminent. For example, notice was issued by
Dr. John D. Stephens, a California physician who informed various
radiologists that he plans to file suit for infringement of his 1991 pat-
ent on an ultrasound procedure which can be used to determine the
gender of a fetus. 32 Public statements of intent to enforce his patent
have been made by the physician who developed the technique
known as "Surrogate Embryo Transfer."'33 A privately held Chicago-
based company, Fertility & Genetics Research funded the develop-
ment of Surrogate Embryo Transfer which was the outcome of the
work of a team led by Dr. John E. Buster at the University of Califor-
nia at Los Angeles. 34 Men's Health Resources, Inc., a group of
urologists who purchased the rights to Dr. Alvaro Latorre's patented
treatment for impotence have threatened hundreds of individual doc-
tors with litigation if they do not pay a $350 per year licensing fee. 35
Also, Yale University has recently confirmed its intention to enforce
a recently issued patent for a method of detecting of breast cancer
tumors by evaluating the presence of Tamoxifen metabolites. 36
The Pallin lawsuit has energized the debate over medical and
surgical procedure patents. Supporters of the legislation argue that
the consent order supports the need for a ban on medical procedure
patents and others, such as the biotechnology industry, claim the out-
come of the lawsuit reaffirms the right to patent any medical break-
through.137
These concerns were recently voiced to the PTO by several in-
terested groups. At hearings to explore ways to improve the quality
of patents and improve the process through which they are issued, 138
131. Public Hearing on Patent Protection for Therapeutic and Diagnostic Methods, supra
note 127.
132. Hearings, supra note 4 (testimony of Charles Kelman, M.D., President American
Society of Cataract and Refractive Surgery); see also U.S. Pat. No. 4,986,274.
133. This technique enables a woman who is infertile or has a genetic disorder to bear a
child fathered by her husband. Hearings, supra note 4 (testimony of Charles Kelman, M.D.,
President American Society of Cataract and Refractive Surgery).
134. Embryo, supra note 97.
135. Hearings, supra note 4 (testimony of Charles Kelman, M.D., President American
Society of Cataract and Refractive Surgery); see also U.S. Pat. No. 4,127,118.
136. Bill Would Limit Issuance, supra note 49; see also U.S. Pat. No. 5,384,260.
137. Craig, supra note 69.
138. Public Hearing on Patent Protection for Therapeutic and Diagnostic Methods, supra
MEDICAL PROCEDURE PATENTS
testimony was presented by representatives of BIO, PhRMA, the In-
tellectual Property Section of the ABA, and the Medical Procedure
Patent Coalition. In addition to raising the issues discussed in the
preceding section, it was argued to the PTO that the medical commu-
nity's professional standards make it distinct. 139 This is because phy-
sicians' ethical duty to share information is much stronger than the
desire to keep secrets and that it is necessary to disseminate informa-
tion about a possible new procedure so that relevant practitioners can
review the inventions and test it.
Several groups argued that in order to preserve the integrity of
the patent system, the rules for securing a patent must be the same for
inventions based on medical or surgical procedures as they are for all
other types of inventions.' 40 In addition, it was noted that there has
been a practical problem with patenting procedures because one can-
not easily determine who really developed them.141 The fear was also
expressed that the lack of availability of patent protection will deter
those anxious to protect proprietary interests in technology from
sharing their knowledge and will force them to employ alternate
means such as trade secret protection.142
The debate continues as to the need for legislative intervention.
The outcome of the Pallin suit indicates that the present system is
working -the judiciary will invalidate patents that should not have
survived the approval process. However, it is clear that the PTO and
the medical community need to make policy changes to adapt to
changes in the subject matter of patent applications which are sub-
mitted. The specialization of medical processes, the need for greater
access to the prior art, and the management of medicine by large cor-
porations must be considered in such policy changes. In addition, the
medical community needs to be educated about the value of patents,
specifically relative to when and where they are appropriate. If this
occurs and patent attorneys and agents follow the rules which require
absolute disclosure of relevant prior art to the PTO, the dilemma of
medical and surgical process patents should not require a legislative
ban on their issue.
note 127.
139. Id.
140. Id.
141. Id.
142. Id.
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VII.ETHICAL CONCERNS SURROUNDING THE PATENTING OF
MEDICAL PROCEDURES
The conflict between the present U. S. patent policy and medical
ethics has created a dilemma for physicians who have an ethical duty
to freely share their knowledge and skills with colleagues for the
public benefit.' 43 Since the time of Hippocrates, physicians have
freely exchanged information ' 44 without the expectation of financial
reward for advancing medical science.' 45 Such sharing has lead to
early dissemination and testing of new techniques and thus rapid im-
provements in technology. ,46
The United States is unique among industrialized nations in
granting patents on pure methods of medical diagnosis and treat-
ment.'47 Proponents of restricting patents on medical procedures em-
phasize that patenting such procedures interferes with the physician-
patient relationship and could lead patent holders to invade patients'
privacy rights while investigating allegations of patent infringe-
ment.
148
The American Medical Association's ethical standards preclude
physicians from patenting medical procedures. 49 Access to optimal
medical care literally affects whether people live or die. These ethi-
cal standards create the dilemma where the value of freedom to
choose the best technique to help a patient must be balanced against
the potential for technical advances and economic benefits based on
143. Adelman, supra note 4; see also Maintaining Confidentiality, 346 LANcET 8984,
Nov. 4, 1995 (arguing that the Hippocratic Oath is unequivocal on the duty of doctors to keep
secret personal information gained in the course of their practice).
144. AMA Criticizes Patenting of Medical Procedures, BNA HEALTH CARE DAILY, June
21, 1995 [hereinafterAMA Criticizes].
145. Id.
146. Hearings, supra note 4 (testimony of Charles Kelman, M.D., President American
Society of Cataract and Refractive Surgery citing AMA ethics: "Physicians have an obligation
to share their knowledge and skills and to report the results of clinical and laboratory research.
This tradition enhances patient care, leads to early evaluation of technological advances, and
permits rapid dissemination of improvements throughout the medical profession").
147. Hearings, supra note 4 (testimony of H. Dunbar Hoskins, Junior Executive Vice-
president Americana Academy of Ophthalmology who testified that Article 52 of the European
Patent Convention expressly excludes from patentability methods of treating people or animals
by surgery, therapy or diagnostic methods practiced on human or animals).
148. Burch, suprariote 96, at 1139.
149. AMA Criticizes, supra note 144 (reviewing The American Medical Association's
Council on Ethical and Judicial Affairs Report, June 19, 1995, Which automatically becomes
AMA policy and criticizing the patenting of medical procedures saying it increases costs and
limits patient access to procedures elevating economic goals above those of patient health and
"severely weakening the integrity" of the profession and note that 40% of the nation's 600,00
physicians are members of the AMA).
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allowance of medical procedure patents. 50
The general public should have open access to any techniques
which may solve a medical problem. Clearly, proprietary interests
should not interfere with dissemination of either new life saving pro-
cedures or incremental improvements which make a medical or sur-
gical procedure more effective. Doctors should not have to worry
about a lawsuit when deciding how to treat their patents. These con-
cerns must be considered in the debate over whether to allow medical
process patents.
VIII. INCENTIVES FOR AWARDING PROPRIETARY RIGHTS TO
MEDICAL PROCEDURES
Know-how encompasses the totality of unpatented knowledge
utilized in the practice of medicine. It is concerned with "detailed
innovation in techniques" of a practical nature that is often the "fruit
of experience and trial and error."'5' The value of know-how results
from incremental improvements in the existing state of technology
and not necessarily from creative activity that raises the level of the
art as a whole. 52 Intellectual property protection tends to eliminate
conventional scientific interaction where information is freely dis-
seminated, and therefore, conflicts with incentives provided to scien-
tists to achieve advancements in science and medicine. 53 It can be
argued that assigning proprietary rights to medical and surgical pro-
cedures contradicts the history of the medical profession where open
exchange of information has occurred through scientific seminars,
textbooks, journal articles, and actual demonstrations. 5 4 Historically,
substantial professional rewards such as prestige and respect have
come to those who have developed new medical and surgical proce-
dures.'55 The current trend is to change this reward system where ex-
change of information occurs spontaneously and encourage physi-
cians to file patent applications. Those who are pro-patent contend
that society rewards inventors with patents because they must be mo-
tivated to exert themselves to create and the potential for obtaining a
150. Noonan, supra note 52, at 265.
151. Reichman, supra note 25, at 656, n79.
152. Id.
153. Aryeh S. Friedman, Law and the Innovative Process: Preliminary Reflections, 1986
COLUM. BUS. L. REv. 1, 7 (1986).
154. Hearings, supra note 4 (testimony of Charles Kelman, M.D., President American
Society of Cataract and Refractive Surgery).
155. AMA Criticizes, supra note 144.
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patent motivates invention15 6 This theory relies on the premise that
inventions require labor; inventors will not invent simply for the love
of it; inventors need external incentives to invent; inventions improve
social welfare, and, therefore, it is worthwhile for society to provide
incentives for inventors1 57 Economic commentators also tend to
frame the purposes of the patent system in incentive-based terms. 58
Three justifications for patent laws which have been proposed
include means to induce individual inventors to put in the effort re-
quired to produce an invention, 59 to induce sponsors to make the
necessary investment required to develop the invention to a commer-
cially viable form,160 and to induce intellectual property owners to
disclose inventions earlier than would otherwise be required.'6'
However, there is no actual evidence to suggest that the patent sys-
tem is necessary to stimulate innovation in the development of medi-
cal and surgical procedures. 62 If patent protection motivates doctors
and scientists to exclude others from making use of research discov-
eries, it undermines interactions in the medical and scientific com-
munities that traditionally advance the state of the art. The tradi-
tional climate in the medical profession -ready sharing of
information and methods -promotes the interests of the community
by the validation of claimed discoveries and sharing of new ideas.
The trend towards patenting creates a dilemma for doctors and scien-
tists who seek current recognition from their peers in the midst of a
competitive environment. In addition, to the extent that the require-
ments for acquiring rights to an invention through a patent go beyond
scientific norms, by mandating broader disclosure than is necessary
to earn recognition in the scientific community, some inventors may
choose to ignore potential patent protection in favor of secrecy.
Sharing access to unique materials and knowledge is important be-
cause it not only enables other doctors and scientists to replicate and
156. Steven Cherensky, A Penny for Their Thoughts: Employee-Inventors, Pre-invention
Assignment Agreements, Property, and Personhood, 81 CAL. L. REV. 597, 636 (1993).
157. Id. See also infra Part IX (noting that in the context of medical techniques, those
that require minimal labor are likely to be developed in the absence of incentives. However,
when the new medical or surgical technique would not have been developed without a large
investment of time, labor or materials, it is imperative that some incentive exist. In the majority
of cases of patents filed for new medical or surgical procedures, it appears they were not the
result of a large investment of time or capital).
158. Ackiron, supra note 35, at 149.
159. Cherensky, supra note 156, at 636-37.
160. Id.
161. Cherensky, supra note 156; see also infra Part IX.
162. A"A Criticizes, supra note 144.
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validate the claims, but it also allows them to compete more effec-
tively in making new discoveries. 1
6
Proponents of the legislation to restrict or eliminate patents on
medical and surgical procedures say the incentives offered should be
the traditional rewards that are available for scientific innovation.
64
Therefore, patents are not needed to encourage innovation of medical
procedures because most are reduced to tangible form in the normal
course of medical practice. 16 In addition, proponents of the legisla-
tion argue that patents on medical procedures will result in price in-
creases based on royalties charged by patent holders and the costs of
patent infringement lawsuits. 66 The development of drugs, medical
devices, and biological products can be extremely expensive due to
research, development, and regulatory approval costs. The promise
of significant financial rewards based on availability of patents is ab-
solutely required as an incentive for those inventions to be created.167
In contrast, there is no significant monetary investment required to
develop the majority of medical and surgical methods, or costly Food
and Drug Administration approval prior to use of a new technique.
Another concern over patented medical and surgical procedures
is that some physicians or health care organizations may choose to
keep their patented invention to themselves and thereby be the exclu-
sive provider of a particular technique, earning more that way than by
collecting royalties. 168 However, innovation in medical practice de-
rives from the work of others169 and is generally the result of intel-
lectual curiosity rather than the result of financial investment in re-
search and development. 170 Therefore, this concern is unlikely to
have a widespread impact.
In recent years, the interest and financial investment on the part
of businesses has changed the focus of medical research in the aca-
demic setting to a more applied and product oriented approach. The
view of the Intellectual Property Law Section of the American Bar
163. Eisenberg, supra note 33, at 188 n52.
164. McCormick, supra note 56, at 35.
165. Do Patents Belong, supra note 2; see also Agency Opposes Bills, supra note 3.
166. Do Patents Belong, supra note 2; see also Bill Would Limit Issuance, supra note 49.
167. Hearings, supra note 4 (testimony of Charles Kelman, M.D., President American
Society of Cataract and Refractive Surgery).
168. McCormick, supra note 56.
169. Bowman, supra note 112 (quoting pioneer transplant surgeon, Thomas Starzl speak-
ing for the American Academy of Surgeons who said "it never would have crossed my mind to
patent a procedure because I knew I was standing on the shoulders of others").
170. Bill Would Limit Issuance, supra note 49.
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Association is that patenting is commonplace in the traditional aca-
demic research setting. Arguably, in the academic setting, discussion
of research results is essential to survival, and patenting and research
occur in harmony in most cases.'7' This negates the argument that
patenting interferes with the process of publication or dissemination
of scientific information. 72 Scientists in other fields tolerate the ef-
fect of patents as part of the process of research and development.
Therefore, singling out medical processes on that basis is question-
able. 73
Not all medical organizations oppose the issuance of patents.
Cedars-Sinai Hospital in Los Angeles adopted a patent policy in 1982
which has resulted in a number of patents and pending applications
on medical products and procedures 74 The policy has made those
procedures and products available to the medical community and has
generated significant revenue for the hospital and its researchers 75
Whereresearch and development are needed to devise and implement
a procedure and where government investment fails to adequately
support research, the availability of patents can motivate investment
in health care by venture capitalists 76 Health maintenance organiza-
tions, clinics, and research institutions generate income through li-
censing and royalty agreements which can only lead to economic
benefits for the medical profession in cases where preliminary in-
vestment of capital is needed. 177
An example supporting the case for medical procedure patents is
the balloon catheter developed at Cedars-Sinai hospital. The device
was described in a publication but not patented and although it was
completely operational, it did not become widely available until pat-
ents were filed on improvements of the device 78 This example is
contrary to the widely held notion that publication promotes dissemi-
nation of scientific information and patenting delays it.
Patent law supposedly promotes investment in innovation by ex-
171. Hearings, supra note 4 (testimony of Donald R. Dunner, ABA Chairman of the In-
tellectual Property Law Section).
172. Id.; see also Burch, supra note 96, at 1160.
173. Hearings, supra note 4 (testimony of Donald R. Dunner, ABA Chairman of the In-
tellectual Property Law Section).
174. Do Patents Belong, supra note 2.
175. Id.
176. Bowman, supra note 112.
177. Do Patents Belong, supra note 2.
178. A. Bloomberg, et al., Patenting Medical Technology: "To Promote the Progress of
Science and UsefulArts," 317 NEw ENG. J. MED. 565,567 (1987).
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cluding others from financially benefiting from another's work.
Those who support this view believe competition is both a cause and
an effect of new and improved products and services as well as in-
creased efficiency in productive processes. Competition motivates
investment in research; the more competitive the industry, the greater
the incentive.179 Therefore, investment in research increases compe-
tition, because the successful innovator gains a competitive advan-
tage over others in the same field who must develop innovations of
their own if they are to stay competitive.180
When a new procedure is developed which would not be devel-
oped without the availability of patent protection, the economic bene-
fits of a patent monopoly outweigh the costs.'8 ' Accordingly, the
value of such a patent on a medical procedure is a function of the cost
and demand for that method. If the development costs of a new tech-
nique are low, the justification for a patent monopoly is weak, re-
gardless of how frequently the procedure is used. 82 However, a
valuable procedure with high research and development costs sup-
ports the case of patentability even if the procedure is not frequently
used. 83 The economic incentives must be balanced with the social
need to make new and helpful methods widely available and to foster
the open sharing of new technology.
In some cases, medical procedure patents will result in increased
dissemination of the information necessary to optimally treat patients
based on the detailed disclosure encompassed in the patent applica-
tion.184 In other situations, the opposite will be true. Certain treat-
ments would not be developed absent the incentive of patent protec-.
tion. 81 Patient privacy and physician autonomy must be subordinate
in importance to the availability of improved health care. 86 Some in-
novations in medical technology will be economically justified or
will be the result of observations made without extraordinary effort,
and therefore, be created without the incentive of patent protection.
This category of innovations, which encompasses the majority of
medical procedures, are usually inexpensive to create. 87 Rewarding
179. Eisenberg, supra note 33, at 218.
180. Id.
181. Burch, supra note 96, at 1161.
182. Id.
183. Id.
184. 35 U.S.C. § 112 (1988) (requiring description of the invention).
185. Id. at 1162.
186. Id.
187. Ackiron, supra note 35, at 150.
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invention with proprietary rights is economically justified only when
the improvement over the existing state of the art would not have
taken place without the patent protection. 188
Basic research will still occur in the absence of the ability to
patent medical processes. However, in cases where the process leads
to a new device or drug, a ban on the process patent could result in
those inventions never being pursued. This would block the matura-
tion of such inventions to a practical and innovative device or drug,
thereby denying the public access to a solution to a medical prob-
lem.I 9 Congress cannot propose an absolute prohibition of medical
process patents without presenting some manner other than private
investment for such research to be funded or society will lose the
benefit of medical advances.
IX. POTENTIAL IMPACT ON THE BIOTECHNOLOGY INDUSTRY
Biotechnology, often referred to as genetic engineering, or re-
combinant DNA research is an area of medically relevant research
that is moving at a rapid pace. This research has already led to the
creation of new products with medical applications such as biophar-
maceuticals and genetic screening tests.190 From 1981 to March of
1995, the FDA had granted approval to sixteen biopharmaceutical
products, including fifteen therapeutics and a vaccine. Overall sales
are expected to grow at an average of twelve percent per year to al-
most $16 billion by 2004.191 Investment in biological research has
yielded an abundance of discoveries. Although few of these products
are presently available to consumers, some are beginning to reach the
marketplace, and more are on the way. This trend suggests that the
biotechnology industry is coming of age. The enormous costs for re-
search and development in biotechnology and the need for long lead
times to recoup the costs of research endeavors has made intellectual
property protections all the more essential for the United States to
maintain a competitive position in the global marketplace. 192 Indus-
try leaders are extremely concerned about the potential impact of a
ban on medical procedure patents. 93 Specifically, the concerns of
188. Id
189. Adler & Murashige, supra note 50.
190. Reichman, supra note 25, at 643.
191. Roger E. Shamel & Michael Keough, Sales of US Biopharmaceutical Products ex-
pected to Triple by 2004, GENETIC ENGMEMG NEWS, March 15, 1995, at 6.
192. Noonan, supra note 52.
193. Agency Opposes Bills, supra note 3.
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industry leaders include the uncertain effect of what is perceived as
vaguely worded legislation on the issuance of patents related to gene
therapy, in vitro diagnostics and biotechnology inventions in gen-
eral.194
Academic medical research centers conduct mainly basic medi-
cal and clinical research. The systematic development of new thera-
peutics has been relegated to private profit-oriented pharmaceutical
companies which have been the source of almost all new drugs in the
last twenty years. 195 This system relies on the pharmaceutical industry
to develop the ideas which derive from basic medical research. The
costs of research and development associated with new drugs or
medical devices are so high that many would not be available today if
the patent system did not exist.196
Until legislation such as the proposed ban on medical and surgi-
cal procedure patents is enacted and interpreted through case law, it
is unclear how far a ban on medical procedure patents would extend
and therefore how much it would impact the biotechnology indus-
try.197 Representatives of the Biotechnology Industry Organization
(BIO)198 argue the risk to innovations in biotechnology is more criti-
cal than any value which may be obtained by a ban'99 and that the
scientific and economic consequences of eliminating "new use" pro-
cedure patents could be devastating to both the pharmaceutical and
biotechnology industries.20
Industry representatives recognize that the major advances in
technology and the manner that research and development is cur-
rently conducted may require adjustments in the patent laws. The
example of the sequencing of the human genome is relevant because
it is generating large amounts of information, but not necessarily
products. However, the information being generated will lead to pat-
entable inventions and products at some point. This is leading com-
panies to protect their discoveries as trade secrets rather than pub-
lishing so they are not precluded from the possibility of later
194. House Adopts Rep. Ganske's Amendment on Funds for Medical Procedure Patents,
supra note 68; see also Craig, supra note 69.
195. Ackiron, supra note 35.
196. Bloomberg, supra note 173.
197. Noonan, supra note 52.
198. BIO represents over 580 companies, academic institutions, state biotechnology cen-
ters and related organizations.
199. Agency Opposes Bills, supra note 3.
200. Noonan, supra note 52.
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patenting their inventions.201
The concerns of the biotechnology and pharmaceutical indus-
tries center around the vagueness of the proposed legislation and the
potential real and perceived impact on active areas of research such
as gene therapy. Industry representatives legitimately fear that even
an inaccurate perception that both biotechnology and pharmaceutical
research and development will be impacted could hurt investment at
a critical time in the evolution of the biotechnology industry.202
X. PROPOSED SOLUTIONS TO THE QUESTIONS SURROUNDING
PATENTING OF MEDICAL AND SURGICAL PROCEDURES
The various options to solving the medical and surgical proce-
dure patent dilemma include legislation such as that presented in the
House and Senate bills, the recent change in the patent statute relat-
ing to damages, 203 and the view that a legislative ban is inappropriate.
At issue is the proper role of the PTO, the proper role of the courts,
and the possibility for a requirement of compulsory licensing based
on industry policy or legislative action.
The creation of the Court of Appeals for the Federal Circuit
(CAFC) as a single forum for appeals in patent case is resulting in
more uniform approaches to interpretation of the patent statutes. The
CAFC has clearly taken the approach that patents are personal prop-
erty.2 4 In parallel, the role of government has grown such that it now
includes the power to regulate the use of property in accordance with
what it sees as the public interests.205 Specific statutory exceptions to
the right to a patent have been justified and therefore enacted in areas
of "public interest. 206
Examples include the inability to patent an invention useful for
incorporation of atomic energy or fissionable material into a nuclear
weapon. 207 In the recent past, the courts have also acted to refine pat-
ent rights and have applied equitable doctrines in denying injunctions
to patent owners. Such a denial effectively grants the alleged in-
201. Adler and Murashige, supra note 50.
202. But see 35 U.S.C § 102(g) (1988) (barring patentability if one suppresses or con-
ceals an invention).
203. See Medical Procedures Innovation and Affordability Act, H.R. 1127 104th Cong.
(1995), and Medical Procedures Innovation and Affordability Act, S. 1334 1127 104th Cong.
(1995).
204. Smith Int'l Inc. v. Hughes Tool Co., 718 F.2d 1573, 1577 (Fed. Cir. 1983).
205. Ackiron, supra note 35.
206. Id.
207. 42 U.S.C. § 2181 (1988).
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fringer a compulsory license.208
A number of situations have arisen where the government re-
quires compulsory licenses on equitable terms. When the government
denies a patent because the technology relates to a weapon system, it
compensates the applicant for any damages caused by a secrecy order
and the government's use of the invention.2 9 The Department of Ag-
riculture may grant compulsory licenses when needed to supply
"fiber, food or feed" if the owner cannot or will not supply the public
needs. 2 0 In addition, the Attorney General may forward a certifica-
tion to a Federal District Court ordering compulsory licensing under
the Clean Air Act for an invention necessary to comply with provi-
sions of the Act when alternatives do not exist and failure to license
would tend to create a monopoly.211 Finally, under the 1980 amend-
ments to the Patent and Trademark Act intended to stimulate bio-
medical research, a patent applicant may be required to license an in-
vention to,the government "at will." This deems the federal govern-
ment immune from injunction for use or manufacture of a patented
invention, while requiring it to pay the patentee "reasonable and en-
tire compensation" for the use thereof.2 2 However, recently the
CAFC has narrowed "public policy" exceptions to the right to a pat-
ent in parallel with actions by Congress to strengthen patent rights. 213
XI. CONCLUSION
Asserting one's claim to a discovery is probably not in itself a
serious threat to the purity or progress of science. This behavior is
part of the competitive attitude that characterizes many of the fastest-
moving arenas of scientific inquiry. The scientific and medical
communities have historically rewarded those who make original
contributions to the pool of knowledge by giving them professional
recognition. Because patent law gives inventors the right to exclude
others from using their discoveries even after public discussion or
208. Ackiron, supra note 35.
209. 35 U.S.C. §§ 181-183 (1988).
210. Plant Variety Protection Act,7 U.S.C. § 2404 (1988).
211. Clean Air Act, 42 U.S.C. § 7608 (1988).
212. 28 U.S.C. § 1498 (1988 & Supp. IV 1992).
213. The Orphan Drug Act, Pub. L. No. 97-414, 96 Stat. 2049 (1983) (codified as
amended in scattered sections of 15, 21, 43, and 45 U.S.C.), the Drug Price Competition Act,
21 U.S.C. § 355 (1988), and the Patent Term Restoration Act of 1984, Pub. L. No. 98-417, 98
Stat. 1585 (1984) (codified as amended at 21 U.S.C. § 321 (1988)), all indicate the support of
the legislature and the judiciary that strong patent protection promotes innovation which in
turn is in the best interest of the general public.
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demonstration of a new method, it can upset the balance of incentives
that have traditionally motivated scientific innovation. The potential
severity of the chilling effect which widespread patenting will have
on innovation is already apparent in patent-driven industries such as
biotechnology where companies routinely have extensive controls on
dissemination of "proprietary" information. This policy often delays
exchange of ideas and discoveries amongst scientists. By allowing
patents on medical and surgical procedures, society pays in terms of
increased health care costs, delayed access to new procedures, inter-
ference with the privacy of the physician-patient relationship, and
loss of medical openness which must be rationalized by a patent pol-
icy. The essential role of innovation and understanding of the moti-
vations that lead to it are important for the progress of medical sci-
ence and must be balanced against successful business strategies to
insure future medical advances.
Based on the three levels of patent law - the Constitutional ba-
sis, the Congressional legislation, and the interpretive case law -
new legislation should not be necessary to stem the tide of unreason-
able claims to ownership of medical and surgical procedures. In the
context of patent infringement suits, courts tend to analyze each in-
vention strictly by interpretation of existing statutes and not consider
the benefit of a particular invention to the general public when mak-
ing a decision as to validity.214 The fact that courts interpret the
statutory law on patent validity in this mechanical manner means that
in the absence of a requirement for compulsory licenses, medical
procedure patents that meet the statutory criteria will lead to enforce-
able patents. This makes it critical that a policy be established which
satisfies the PTO and the relevant groups which have expressed con-
cern over this issue, and the policy should require compulsory li-
censing in order to get relevant inventions out into the general public.
If policy does not work, a statutory change such as enacted relative to
nuclear weapons and the Plant Variety Protection Act and the Clean
Air Act will be needed. Allowing such legislation may restrict in-
dustries which exist on the periphery of the medical community and
depend upon proprietary rights for survival.
In order to evaluate whether the patenting of medical and surgi-
cal techniques is appropriate, such processes may be analyzed in
terms of those that require minimal investment or significant invest-
ment to develop. The techniques can be divided into two categories:
one which represents an incremental change in existing technology
214. Burch, supra note 96, at 1150.
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and one which represents a significant advance. Patent protection is
appropriate where innovation requires investment for research, de-
velopment, and regulatory costs. When investment is required in or-
der to develop the new medical or surgical method, it is imperative
that an incentive exists in order to attract the necessary capital.
The majority of patent applications filed for new medical or sur-
gical procedures fall into the first category: they represent technical
advances that make a procedure more effective or efficient but are
not the result of a large investment of time or capital.215 Some tech-
niques which are incremental technical advances may not satisfy the
criteria of a patentable invention based on a lack of novelty or be-
cause they would have been obvious to those with ordinary skill in
the art.216 The existing patent laws will weed out such patent appli-
cations either in the approval process or will invalidate the patent in
the courts. This assumes the PTO improves the ability to do prior art
searches which must encompass non-published references including
video tapes of procedures (which are the most common way medical
or surgical procedures are taught). The PTO should hire specialists
or consultants when necessary to be sure prior art searches are com-
plete, and the PTO must also be more effective in evaluating where
patent protection is deserved. Incremental advancements in a tech-
nique should not qualify for patent protection and the best place to
resolve disputes as to the significance of an "invention" is in the PTO
approval process. If inventions which are not deserving of patent
protection are awarded a patent, such as in the Pallin case, the courts
should be able to negate the presumption of validity based on a find-
ing of lack of novelty or obviousness in the context of an infringe-
ment action.
The need for medical procedure patents to foster innovation is
not compelling in cases where minimal investment is required and
the extent to which the majority of such medical or surgical tech-
niques will require the incentive of patent protection in order to be
developed cannot overcome the potential social costs and ethical is-
sues of allowing such patents to issue and be upheld. Social costs in-
clude reduced access to such procedures due to exclusive use by the
patentee or unavailability due to increased costs. There would be an
impact on the open sharing of information and public discussion of
new techniques such that the corresponding peer evaluation would
decrease. In addition, interference with the physician-patient rela-
215. See infra Part VII.
216. See 35 U.S.C. § 103 (1988).
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tionship by invasion of patient privacy when investigating allegations
of patent infringement clearly raises ethical concerns and could not
be justified for inventions that require minimal investment. How-
ever, a ban is not required because the existing system will either
weed out such "inventions" or it can be modified to negate patenting
when it is not appropriate without a major revision of the patent laws.
In contrast, the availability of medical and surgical procedure
patents is imperative for advances that require significant investment.
This creates a paradox because of the ethical and social concerns as-
sociated with allowing such patents. A complete ban on medical
procedure patents may mean that a life saving technique would not be
developed because research and development costs are too high to
justify the expense without a patent as a financial incentive. The con-
cern that such techniques would not be available in the absence of
economic incentives gains significance as large health care organiza-
tions concerned about the bottom line take over management of pa-
tient care. They will require some incentive to be willing to invest in
development of new methods. The difficulty in evaluating the impact
of restrictive legislation is more critical in such cases where the so-
cial costs and ethical issues are more easily rationalized.
The damage which a ban on medical procedure patents could do
to the biotechnology and pharmaceutical industries is also a key fac-
tor in determining if support for restrictive legislation is appropriate.
Any new legislation will have to allow patenting to continue in those
industries. If the Senate version of the Medical Procedures Innova-
tion and Affordability Act (or something like it) is passed, one cannot
predict where the courts will draw the line as to what is a pure proce-
dure and what is a "necessary component of a patentable medical de-
vice wherein the patent claims the technique, method or process. '217
The definitions of "medical practitioner" and "medical activity" in
the recently approved legislation raise similar concerns.
In any event, a patent should not be a windfall to the owner, but
fair compensation to justify the business risk and pay for the inven-
tive effort. A legislative ban is not the most effective way to accom-
plish that goal. An industry policy such as the compulsory licensing
required by statute under the Plant Variety Protection Act,218 the
Clean Air Act,219 and the 1980 amendments to the Patent and Trade-
217. Medical Procedures Innovation and Affordability Act, H.R. 1127, 104th Cong.
(1995).
218. Plant Variety Protection Act, 7 U.S.C. § 2404 (1988).
219. Clean Air Act, 42 U.S.C. § 7608 (1988).
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mark acts,220 could provide an incentive to innovate by fairly com-
pensating for development costs while, at the same time, minimizing
the harmful effects of exclusivity in this context.
The problem with medical process patents stems from the
change in the way the medical profession is run: increasingly like a
business. We cannot escape the fact that physicians and health care
organizations want to own inventions and capitalize on them. Nor is
it realistic to assume that they will not find a way to do so even if
they cannot obtain a patent. Any change in the law or policy to deal
with this problem must promote disclosure. To encourage protection
of inventions as trade secrets is the-worst possible outcome and could
be the result of a ban on medical and surgical procedure patents.
Work must be done to create a consistent well-defined PTO policy
and improve access to relevant prior art. In addition, compulsory li-
censing should be required in cases where a technique is needed to
save lives or make a procedure more effective. Any compulsory li-
censing must require fair compensation to the patentee. Also, the
PTO must actively deter inequitable conduct - such as non-
disclosure of material prior art - and encourage patent attorneys and
agents to present a fair case to the PTO for effective prosecution.
Many new medical techniques will not pass the requirements of
the PTO and be denied a patent. Still others will be invalidated in the
court system. A combination of these two levels of control with a
strong industry policy regarding promotion of access to new tech-
niques is imperative especially where there is no existing solution to
a medical problem.
220. The Orphan Drug Act, Pub. L. No. 97-414, 96 Stat. 2049 (1983) (codified as
amended in scattered sections of 15, 21, 43, and 45 U.S.C.), the Drug Price Competition Act,
21 U.S.C. § 355 (1988), and the Patent Term Restoration Act of 1984, Pub. L. No. 98-417, 98
Stat. 1585 (1984) (codified as amended at 21 U.S.C. § 321 (1988)), all indicate the support of
the legislature and the judiciary that strong patent protection promotes innovation which in
turn is in the best interest of the general public.'
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